UnknownNot Applicable

NT-proBNP Levels During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.

Italy29 participantsStarted 2022-06-28

Plain-language summary

Observational prospective study to evaluate serum NT-proBNP levels in a population of COPD patients three months after the iniation of triple inhaled formoterol/glycopyrrolate/budesonide therapy.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * COPD; * Clinical indication for triple inhalation therapy with formoterol/glycopyrrolate/budesonide; Exclusion Criteria: * Life expectancy less than one year;

What they're measuring

Change in serum NT-pro-BNP levels

Timeframe: Before and 3 months after the start of triple therapy with formoterol/glycopyrrolate/budesonide

Trial details

NCT IDNCT06317428

SponsorIstituto Nazionale di Ricovero e Cura per Anziani

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-31

Contact for this trial

Anna Rita Bonfigli

0718003719 a.bonfigli@inrca.it

View on ClinicalTrials.gov More COPD trials